At AstraZeneca, we are committed to transforming renal care by rapidly advancing our ambition to create a coordinated pathway for CKD patients through strategic partnerships and deepening our knowledge around the burden of this disease.
We aim to provide new and innovative solutions that empower people living with CKD, along with real-world evidence that allows us to better understand current treatment patterns and the full impact of the disease. We know this is needed now more than ever as we emerge from the COVID-19 pandemic, which has taken a significant toll on people living with CKD. It’s clear we need to take bold action to advance CKD care and encourage important public health changes that address the needs of the renal community.
We spoke with two of our leaders at AstraZeneca, Helen Yeh and Ruud Dobber, about the unmet medical need in CKD and our ambition to help drive awareness, earlier detection and intervention, and ultimately halt the progression of this devastating disease.
Why do we need to take action now on reducing the burden of CKD?
Helen Yeh, Vice President, Cardiovascular, Renal & Metabolism (CVRM), BioPharmaceuticals Medical, AstraZeneca, discusses the importance of working with patients and physicians to understand unmet medical need in CKD and the role of real-world evidence in uncovering important insights that help to address these challenges.
How is AstraZeneca working with others to address the significant unmet need in CKD?
Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, highlights our ambition to stop, reverse and cure kidney disease through scientific leadership, innovative partnerships and earlier diagnosis. By taking a multi-pronged approach, we aim to transform kidney care for patients and healthcare providers.
Patients remain at the centre of our efforts. By going beyond the science to drive awareness and earlier diagnosis of CKD, we aim to help patients live longer and happier lives.
1. Bruchfeld A, et al. The COVID-19 pandemic: consequences for nephrology. Nat Rev Nephrol 17, 81–82 (2021).